Announcements Trials
Browse Landscape

Phase

Phase 2 69Phase 1 42Phase 1/2 34Phase 3 22Phase EARLY_PHASE1 2Phase 2/3 2Phase NA 1Phase 4 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma 2Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1

Interventions

Magnetic Resonance Spectroscopy 23Metformin 14pembrolizumab 12Radiotherapy 12Biopsy 11Nivolumab 9Fluorouracil 9Cyclophosphamide 9Temozolomide 7Radiation 7Bevacizumab 7gallium 68 PSMA-11 6Sirolimus 6Rituximab 6Letrozole 6Etoposide 6Cisplatin 6Aspirin 6olaparib 5Surveys and Questionnaires 5Radiosurgery 5Oxaliplatin 5Irinotecan 5Indocyanine Green 5Granulocyte Colony-Stimulating Factor 5Fluorodeoxyglucose F18 5Dexamethasone 5aldesleukin 4Surgical Procedures, Operative 4Proflavine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Completed × Bendamustine Hydrochloride × Clear all
NCT03295240 2025-05-13

The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma

Memorial Sloan Kettering Cancer Center

Phase EARLY_PHASE1 Completed
10 enrolled
Lymphoid

Lymphoma, Lymphoma, Mantle-Cell

NCT01022021 2017-01-10

Peripheral Blood Stem Cell (PBSC) Mobilization in Patients With Relapsed Lymphoma Treated With Bendamustine

University of Kansas Medical Center

Phase EARLY_PHASE1 Completed
17 enrolled
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡